Marksans Pharma has received approval from the US health regulator for Paricalcitol capsules, used for treating hyper parathyroidism.
"USFDA (US Food & Drug Administration) has granted approval for an abbreviated new drug application (ANDA) for Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg," Marksans Pharma said in a BSE filing today.
Paricalcitol Capsules are therapeutically equivalent to the reference listed drug Zemplar Capsules 1 mcg, 2 mcg and 4 mcg.
Paricalcitol Capsules is a synthetic Vitamin D analog.
"Vitamin D is important for absorption of Calcium from the stomach and for functioning of Calcium in the body. Paricalcitol is used to treat or prevent hyper parathyroidism," the company said.
Shares of Marksans were trading 3.47 per cent up at Rs 55.10 apiece on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)